Pharmaceutical News

RSS

Negative perceptions about generic drugs are more widespread among ethnic minorities

Negative perceptions about generic drugs are more widespread among ethnic minorities than among whites, finds a new study in Ethnicity & Disease.

1 Dec 2012

Epidural steroid injections for back pain increase risk of bone loss in postmenopausal women

Postmenopausal women suffered significant bone density loss in their hip after they were treated with an epidural steroid injection for back pain relief, according to a Henry Ford Hospital study

1 Dec 2012

NAP and SAL injection during pregnancy improve memory, learning tasks in offsprings

Mice with a condition that serves as a laboratory model for Down syndrome perform better on memory and learning tasks as adults if they were treated before birth with neuroprotective peptides, according to researchers at the National Institutes of Health.

30 Nov 2012

Mistletoe extract plays a vital role in treating colon cancer

Mistletoe has become an important symbol of Christmas but it also has the potential to play a vital role as an alternative therapy for sufferers of colon cancer.

30 Nov 2012

Vitamin D may be vital component for cognitive health of women

Two new studies appearing in the Journals of Gerontology Series A: Biological Sciences and Medical Sciences show that vitamin D may be a vital component for the cognitive health of women as they age.

30 Nov 2012

Sucampo receives supplement approval from FDA for AMITIZA

Sucampo Pharmaceuticals, Inc. today announced that the Company received a supplement approval from the U.S. Food and Drug Administration (FDA) that removes pregnancy "warnings and precautions" and clarifies information regarding the use of AMITIZA (lubiprostone) by pregnant and/or nursing women. In addition, the FDA expanded the labeling text of the Mechanism of Action section in the prescribing information for AMITIZA.

30 Nov 2012

European health officials warn Greece to address increasing number of HIV cases

Officials with the European Centre for Disease Prevention and Control (ECDC) said Greece must act to combat a rising number of HIV cases within high-risk populations, including drug users, or face increased health care costs in the future, Reuters reports.

30 Nov 2012

More widespread HIV treatment helped South Africa increase life expectancy, researchers say

With the average life expectancy for South Africans at 60 years old, the country "has achieved a 'stunning' increase in life expectancy in the last three years due to a government push to roll out antiretroviral drugs (ARVs) to people with HIV/AIDS," according to a study published in the Lancet on Thursday, Reuters reports.

30 Nov 2012

Today's teens and young people more likely to abuse prescription painkillers

Today's teens and young people are abusing prescription painkillers more than any other age group or any other youth in history. Availability of these drugs from their parents' medicine cabinets may be to blame, according to new research in the Journal of Adolescent Health.

30 Nov 2012

Secretary Clinton unveils 'blueprint' for achieving 'AIDS-free generation'

"Secretary of State Hillary Clinton on Thursday unveiled a game plan for achieving a global 'AIDS-free generation,' committing the United States to rapidly scaling up medical interventions that are beating back what once was seen as an unconquerable disease," Reuters reports.

30 Nov 2012

Eisai announces FDA acceptance of AcipHex NDA for priority review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.

30 Nov 2012

JQ1 cancer drug may be useful in purging latent HIV infection

Breakthrough drugs have made it possible for people to live with HIV longer than ever before, but more work must be done to actually cure the disease. One of the challenges researchers face involves fully eradicating the virus when it is latent in the body.

30 Nov 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

30 Nov 2012

CSL, PharmaJet partner for needle-free delivery of Afluria influenza vaccine

PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season.

30 Nov 2012

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

LP-211 compound shows promise against Fragile X syndrome

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

29 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012